-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hutchison Medicine announced that it has initiated a phase I clinical trial of HMPL-295
The study is a multi-center, open-label clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy characteristics of HMPL-295, and to determine the maximum tolerated dose in patients with advanced malignant solid tumors And the recommended dose of Phase II clinical study (RP2D)
Hutchison Pharmaceuticals currently owns all rights of HMPL-295 worldwide